Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.

Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ.

J Clin Oncol. 2003 May 15;21(10 Suppl):206s-210s.

PMID:
12743136
2.

A randomized study of screening for ovarian cancer: a multicenter study in Japan.

Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T.

Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20. Epub 2007 Jul 21.

PMID:
17645503
3.
4.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

5.

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.

Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RH.

J Clin Oncol. 2007 Apr 10;25(11):1383-9.

PMID:
17416858
6.

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IeM.

J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703.

PMID:
12441325
7.

Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.

Cane P, Azen C, Lopez E, Platt LD, Karlan BY.

Gynecol Oncol. 1995 May;57(2):240-5.

PMID:
7729742
8.

Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.

Vuento MH, Stenman UH, Pirhonen JP, Mäkinen JI, Laippala PJ, Salmi TA.

Gynecol Oncol. 1997 Jan;64(1):141-6.

PMID:
8995563
9.

Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.

Jeyarajah AR, Ind TE, Skates S, Oram DH, Jacobs IJ.

Cancer. 1999 May 1;85(9):2068-72.

PMID:
10223249
10.

The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.

de Bruijn HW, van der Zee AG, Aalders JG.

Curr Opin Obstet Gynecol. 1997 Feb;9(1):8-13. Review.

PMID:
9090475
11.

Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.

Whitmore SE, Anhalt GJ, Provost TT, Zacur HA, Hamper UM, Helzlsouer KJ, Rosenshein NB.

Gynecol Oncol. 1997 May;65(2):241-4.

PMID:
9159332
12.

Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.

Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C.

Acta Obstet Gynecol Scand. 2009;88(1):18-26. doi: 10.1080/00016340802443830.

PMID:
19023702
13.
14.

Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.

Einhorn N, Sjövall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, Zurawski VR Jr.

Obstet Gynecol. 1992 Jul;80(1):14-8.

PMID:
1603484
15.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

PMID:
16343244
16.

Diagnostic markers for early detection of ovarian cancer.

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.

Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308. Clin Cancer Res. 2008 Nov 1;14(21):7158.

17.

Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.

Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.

Acta Obstet Gynecol Scand. 2008;87(11):1136-42. doi: 10.1080/00016340802478158.

PMID:
18951217
18.

Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

Skates SJ, Xu FJ, Yu YH, Sjövall K, Einhorn N, Chang Y, Bast RC Jr, Knapp RC.

Cancer. 1995 Nov 15;76(10 Suppl):2004-10.

PMID:
8634992
19.

The performance of screening tests for ovarian cancer: results of a systematic review.

Bell R, Petticrew M, Sheldon T.

Br J Obstet Gynaecol. 1998 Nov;105(11):1136-47. Review.

PMID:
9853761
20.

Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer.

Brockbank EC, Ind TE, Barton DP, Shepherd JH, Gore ME, A'Hern R, Bridges JE.

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):42-50.

PMID:
14764028

Supplemental Content

Support Center